SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$189M
Q4 2018
Positions
48
Filings on Record
24
2019–present window
Filed
Feb 14, 2019
original filing

Summary

Endurant Capital Management LP reported $189M in U.S.-listed holdings across 48 positions for Q4 2018.

Its largest position, Allergan, represents 8.4% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+53.5%
share of reported value
Largest Position
+8.4%
Allergan

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 67.0%Other: 29.2%ADR: 2.5%US DOMESTIC: 1.3%
  • Common Stock · 67.0% · $127M
  • Other · 29.2% · $55M
  • ADR · 2.5% · $5M
  • US DOMESTIC · 1.3% · $3M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
ALLERGAN PLCNEW+119.1K119.1K+$16M$16M
CICIGNA CORP NEWNEW+70.9K70.9K+$13M$13M
ZBHZIMMER BIOMET HLDGS INCNEW+123.9K123.9K+$13M$13M
CELGCELGENE CORPNEW+168.6K168.6K+$11M$11M
CVSCVS HEALTH CORPNEW+147.6K147.6K+$10M$10M
MEDTRONIC PLCNEW+92.8K92.8K+$8M$8M
SHIRE PLCNEW+46.1K46.1K+$8M$8M
WRIGHT MED GROUP N VNEW+282.1K282.1K+$8M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ALLERGAN PLCSHS8.41%$16M119.1K
2CICIGNA CORP NEWhistory →COM7.12%$13M70.9K
3ZBHZIMMER BIOMET HLDGS INChistory →COM6.79%$13M123.9K
4CELGCELGENE CORPhistory →COM5.71%$11M168.6K
5CVSCVS HEALTH CORPhistory →COM5.11%$10M147.6K
6MEDTRONIC PLCSHS4.46%$8M92.8K
7SHIRE PLCSPONSORED ADR4.24%$8M46.1K
8WRIGHT MED GROUP N VORD SHS 0.03 PAR4.06%$8M282.1K
9TRLDAVITA INChistory →COM3.83%$7M140.7K
10RCMEURR1 RCM INChistory →COM3.75%$7M893.4K
11IINUSDINTRICON CORPhistory →COM3.46%$7M248.0K
12OXFORD IMMUNOTEC GLOBAL PLCORD SHS3.12%$6M461.2K
13AL21ALLSCRIPTS HEALTHCARE SOLUTNhistory →COM3.01%$6M591.5K
14HO1HOLOGIC INChistory →COM2.95%$6M135.8K
15ICON PLCSHS2.81%$5M41.1K
16EHCENCOMPASS HEALTH CORPhistory →COM2.78%$5M85.3K
17FLBFLUIDIGM CORP DELNOTE 2.750% 2/0 · COM2.41%$5M2.99M
18XRAYDENTSPLY SIRONA INChistory →COM2.33%$4M118.4K
19UNHUNITEDHEALTH GROUP INChistory →COM2.20%$4M16.7K
20SNYSANOFIhistory →SPONSORED ADR1.87%$4M81.4K
21PODDINSULET CORPhistory →COM1.71%$3M40.7K
22BHCBAUSCH HEALTH COS INChistory →COM1.60%$3M163.9K
23IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.49%$3M318.2K
24BMYBRISTOL MYERS SQUIBB COhistory →COM1.36%$3M49.3K
25SRPTSAREPTA THERAPEUTICS INChistory →COM1.25%$2M21.6K
26NVROEURNEVRO CORPhistory →COM1.13%$2M55.0K
27MYLAN N VSHS EURO1.12%$2M77.1K
28OSMOTICA PHARMACEUTICALS PLCSHS0.95%$2M232.0K
29PETSPETMED EXPRESS INCCOM0.82%$2M67.0K
30XEJACCURAY INCCOM0.82%$2M455.0K
31ARRYEURARRAY BIOPHARMA INCCOM0.77%$1M102.3K
32IRTCIRHYTHM TECHNOLOGIES INCCOM0.66%$1M18.0K
33SYKSTRYKER CORPCOM0.61%$1M7.3K
34TEVATEVA PHARMACEUTICAL INDS LTDSPONSORED ADR0.60%$1M73.9K
35BSXBOSTON SCIENTIFIC CORPCOM0.57%$1M30.6K
36OCULOCULAR THERAPEUTIX INCCOM0.49%$926,000232.7K
37JNJJOHNSON & JOHNSONCOM0.45%$850,0006.6K
38LQDALIQUIDIA TECHNOLOGIES INCCOM0.45%$848,00039.1K
39AXGNAXOGEN INCCOM0.43%$816,00040.0K
40ANABANAPTYSBIO INCCOM0.43%$812,00012.7K
41ABGAMERISOURCEBERGEN CORPCOM0.33%$620,0008.3K
42AXSMAXSOME THERAPEUTICS INCCOM0.31%$590,000209.2K
43AM6AMICUS THERAPEUTICS INCCOM0.29%$558,00058.2K
44ALDXALDEYRA THERAPEUTICS INCCOM0.29%$553,00066.6K
45MCKMCKESSON CORPCOM0.29%$549,0005.0K
46VKTXVIKING THERAPEUTICS INCCOM0.22%$409,00053.5K
47KRYSKRYSTAL BIOTECH INCCOM0.14%$260,00012.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.